Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer
January 14 2020 - 9:00AM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for debilitating liver diseases, today announced the
promotion of Ian Clements to Chief Financial Officer. Dr. Clements
joined Mirum in March 2019 and most recently served as Senior Vice
President, Finance and Communications.
“Since joining Mirum, Ian has played a pivotal role in the
growth and success of the company,” said Chris Peetz, president and
CEO. “Ian’s financial leadership through our IPO and recent
financing has positioned us well for the upcoming planned NDA
filing of maralixibat for pruritus due to Alagille syndrome,
providing us with the financial resources expected to last the
company through the potential approval.”
Prior to joining Mirum, Dr. Clements served as Vice President of
Investor Relations at Dermira, Inc. Previously, Dr. Clements served
as Vice President, Investor Relations and Corporate Communications
at Tobira. Prior to that, he was head of investor relations and
corporate communications at Avanir Pharmaceuticals. Dr. Clements
has also held leadership positions at Sequenom, a genetic analysis
and diagnostics company, and The Trout Group, where he managed west
coast operations for life sciences investor relations. Dr. Clements
received a Ph.D. in chemistry from the University of Manchester, an
MBA from the Open University in the United Kingdom and a B.Sc. in
chemistry from Staffordshire University.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. The company’s lead product candidate,
maralixibat, is an investigational oral drug in development for
progressive familial intrahepatic cholestasis (PFIC) and Alagille
syndrome (ALGS). For more information, visit MirumPharma.com.
Follow Mirum on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, the planned NDA filing and potential
approval for maralixibat and the adequacy of the company’s
financial resources. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “plans,” “will,” “believes,” “anticipates,” “expects,”
“intends,” “goal,” “potential” and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements are based upon Mirum’s current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with Mirum’s business in
general, and the other risks described in Mirum’s filings with the
Securities and Exchange Commission , including without limitation
in its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2019. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Mirum undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200114005057/en/
Media Contact: Heidi
Chokeir, Ph.D. Canale Communications 619-203-5391
heidi@canalecomm.com
Investor Contact: Ian
Clements, Ph.D. 650-667-4085 ir@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024